PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 16020511

CD molecules 2005: human cell differentiation molecules.

Heddy Zola·Bernadette Swart·Ian Nicholson·Bent Aasted·Armand Bensussan·Laurence Boumsell·Chris Buckley·Georgina Clark·Karel Drbal·Pablo Engel·Derek Hart·Václav Horejsí·Clare Isacke·Peter Macardle·Fabio Malavasi·David Mason·Daniel Olive·Armin Saalmueller·Stuart F Schlossman·Reinhard Schwartz-Albiez·Paul Simmons·Thomas F Tedder·Mariagrazia Uguccioni·Hilary Warren
View original source ↗Export metadata ↓

Abstract

The immune system works through leukocytes interacting with each other, with other cells, with tissue matrices, with infectious agents, and with other antigens. These interactions are mediated by cell-surface glycoproteins and glycolipids. Antibodies against these leukocyte molecules have provided powerful tools for analysis of their structure, function, and distribution. Antibodies have been used widely in hematology, immunology, and pathology, and in research, diagnosis, and therapy. The associated CD nomenclature is commonly used when referring to leukocyte surface molecules and antibodies against them. It provides an essential classification for diagnostic and therapeutic purposes. The most recent (8th) Workshop and Conference on Human Leukocyte Differentiation Antigens (HLDA), held in Adelaide, Australia, in December 2004, allocated 95 new CD designations and made radical changes to its aims and future operational strategy in order to maintain its relevance to modern human biology and clinical practice.

Explore related subjects

Antigens, CDCell DifferentiationHumansReproducibility of ResultsTerminology as TopicJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Heddy Zola, Bernadette Swart, Ian Nicholson, Bent Aasted, Armand Bensussan, Laurence Boumsell, Chris Buckley, Georgina Clark, Karel Drbal, Pablo Engel, Derek Hart, Václav Horejsí, Clare Isacke, Peter Macardle, Fabio Malavasi, David Mason, Daniel Olive, Armin Saalmueller, Stuart F Schlossman, Reinhard Schwartz-Albiez, Paul Simmons, Thomas F Tedder, Mariagrazia Uguccioni, Hilary Warren. 2005-07-14. CD molecules 2005: human cell differentiation molecules.. https://doi.org/10.1182/blood-2005-03-1338

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Autophagic-like cell death in neutrophils induced by autoantibodies.

Human neutrophils undergo autophagic-like cell death following Sialic acid binding immunoglobulin-like lectin-9 (Siglec-9) ligation and concurrent stimulation with certain, but not all, neutrophil survival cytokines. Caspase inhibition by these cytokines is required, but is not sufficient, to trigger this particular form of cell death. Additional mechanisms may involve reactive oxygen species (ROS), and blocking of ROS or prevention of ROS production prevents autophagic-like neutrophil death. Interestingly, human intravenous immunoglobulin (IVIg) preparations contain natural anti-Siglec-9 autoantibodies, which are able to ligate Siglec-9 on neutrophils and induce autophagic-like cell death in the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF) and some other survival cytokines. Here, we discuss the pathophysiological and therapeutic implications of these recent findings.

Antigens, CD↗
PubMed2007

Bias in association studies of systemic lupus erythematosus susceptibility due to geographical variation in the frequency of a programmed cell death 1 polymorphism across Europe.

We obtained eight collections of DNA samples from ethnically matched systemic lupus erythematosus (SLE) patients and controls from five European countries totaling 783 patients and 1210 controls. A highly significant cline in the frequency of the PD1.3 A allele was found among controls but not among SLE patients. The frequency of the PD1.3 A allele increased from the Northeast to the Southwest of Europe. The cline was clearly apparent (P=1.2 x 10(-6)) when data from controls of other five SLE susceptibility studies were included in the analysis. This variation has severely biased SLE association studies owing to the lack of parallel changes in SLE patients. As a consequence, the PD1.3 A allele was more common in SLE patients than in controls in the Northeast and Center of Europe, similar to controls in Southeast Europe, and less frequent than in the controls in the Southwest of the Continent. This dissociation in allele frequencies between SLE patients and controls in different subpopulations indicated that programmed cell death 1 variation and disease susceptibility are not independent but the type of relationship is currently unclear. As allele frequency clines are common in other polymorphisms their impact in genetic epidemiology studies should be carefully considered.

Antigens, CD↗